Schering Slows Its Slide
21687
After the bad Vytorin news, Schering's CEO puts his money where his mouth is.
271632
Pharmaceutical stocks were mixed in afternoon trading, performing slightly better than the Dow Jones Industrial Average but seeing sharp declines in smaller stocks on clinical trial snags.
710953
The software maker is moving along -- but not enough to get investors excited.
738382
The drug maker is poised to speed past its rivals.
24676
Bayer AG forged an alliance for its struggling pharmaceuticals business with US drugmaker Schering-Plough on Monday, cutting costs and marking another step in the German company&#39;s transformation.
298049
The pharmaceutical company reported a 5 percent increase in fourth-quarter earnings but said growth would slow this year as generic competition picked up.
65620
Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter.
404937
Schering gets a haircut after missing earnings.
622659
German drugmaker Schering expects a  U.S. launch for a low-dose form of its key contraceptive drug  Yasmin in the second half of next year, its head said on  Wednesday.
583813
It takes another run at getting FDA approval for its lead drug.
271921
The reduction in patients for Amylin's Byetta diabetes drug could be small.
83518
Merck & Co and Schering-Plough Corp said a closely watched study involving its Vytorin cholesterol treatment failed to reach its main goal.
677970
A very early test of an experimental drug seemed to slow the spread of advanced deadly skin cancer in a small study, the drug's U.S. developer reported in preliminary findings Wednesday.
122773
The drugmaker Bayer AG said Friday that it will cut 6,100 jobs, or 5.5 percent of its work force, as it integrates Schering AG into its health care unit. More than half of the cuts will be in Europe, but about 1,000 positions will be eliminated in the United States.
457661
U.S. regulators need more clinical trials before they can approve heart-scan contrast agent MS-325 from Germany's Schering and U.S. partner Epix Pharmaceuticals, the companies said on Friday.
346072
US manufacturing grew at a slower pace in September, as new orders slowed, a private industry survey showed. Manufacturing ``has cooled from the blistering pace, though activity remains
23643
With help of longtime partner, German software maker dips toe in market it had downplayed.